Clinical study of Guanxin Shutong Capsules combined with recombinant human brain natriuretic peptide in treatment of chronic heart failure
Objective To analyze the clinical efficacy of Guanxin Shutong Capsules combined with recombinant human brain natriuretic peptide in treatment of chronic heart failure.Methods A total of 122 patients with chronic heart failure admitted to Weinan Central Hospital from January 2021 to November 2023 were selected and divided into control group and treatment group according to random number table method,with 61 patients in each group.Patients in the control group were given Lyophilized Recombinant Human Brain Natriuretic Peptide,intravenous infusion at a dosage of 1.5 μg/kg was followed by continuous intravenous infusion at a rate of 0.007 5 μg/(kg∙min)for 3 d,after which conventional treatment was continued.Patients in the treatment group were po administered with Guanxin Shutong Capsules on the basis of the control group,3 capsules/time,3 times daily.Both groups were treated continuously for 2 weeks.After treatment,the clinical efficacy was evaluated,and the levels of left ventricular ejection fraction(LVEF),left ventricular end diastolic volume(LVEDV),Barthel index(BI)score,6-minute walking distance(6MWD),heart rate variability indicators[standard deviation of normal cardiac cycle(SDNN),root mean square difference between adjacent normal cardiac cycles(rMSDD)],and serum N-terminal B-type natriuretic peptide(NT proBNP),cardiac troponin I(cTnI),interleukin-6(IL-6),and hypersensitive C-reactive protein(hs CRP)levels before and after treatment were compared.Results After treatment,the total effective rate of treatment group was 95.08%,which was significantly higher than that of control group(83.61% )(P<0.05).After treatment,LVEF and BI scores and 6MWD were significantly increased,while LVEDV was significantly decreased in both groups(P<0.05).After treatment,LVEF,LVEDV,BI scores,and 6MWD were significantly improved in the treatment group(P<0.05).After treatment,SDNN,rMSDD,and SDANN were significantly increased in both groups(P<0.05),and more significantly in the treatment group(P<0.05).After treatment,the levels of serum NT-proBNP,cTnI,IL-6,and hs-CRP in two groups were significantly decreased(P<0.05),and more significantly in the treatment group(P<0.05).Conclusion Guanxin Shutong Capsules combined with recombinant human brain natriuretic peptide has exact effect in treatment of chronic heart failure with good safety,and can effectively improve the heart function of patients,promote the recovery of life ability and exercise endurance,which can reduce the inflammatory injury and myocardial damage.
Guanxin Shutong CapsulesLyophilized Recombinant Human Brain Natriuretic Peptidechronic heart failureIL-6hs-CRP
NETL
NSTL
万方数据
